These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30404440)
41. A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action. Paulmurugan R; Tamrazi A; Katzenellenbogen JA; Katzenellenbogen BS; Gambhir SS Mol Endocrinol; 2008 Jul; 22(7):1552-64. PubMed ID: 18451095 [TBL] [Abstract][Full Text] [Related]
42. Symmetric 4,4'-(piperidin-4-ylidenemethylene)bisphenol derivatives as novel tunable estrogen receptor (ER) modulators. Sato M; Ohta K; Kaise A; Aoto S; Endo Y Bioorg Med Chem; 2016 Mar; 24(5):1089-94. PubMed ID: 26822566 [TBL] [Abstract][Full Text] [Related]
43. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364 [TBL] [Abstract][Full Text] [Related]
44. Enhanced estrogen receptor beta (ERβ) selectivity of fluorinated carborane-containing ER modulators. Ohta K; Ogawa T; Kaise A; Endo Y Bioorg Med Chem Lett; 2013 Dec; 23(24):6555-8. PubMed ID: 24268550 [TBL] [Abstract][Full Text] [Related]
45. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Carlson KE; Choi I; Gee A; Katzenellenbogen BS; Katzenellenbogen JA Biochemistry; 1997 Dec; 36(48):14897-905. PubMed ID: 9398213 [TBL] [Abstract][Full Text] [Related]
46. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652 [TBL] [Abstract][Full Text] [Related]
47. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens. Suba Z Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776 [TBL] [Abstract][Full Text] [Related]
48. Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489 [TBL] [Abstract][Full Text] [Related]
49. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711 [TBL] [Abstract][Full Text] [Related]
50. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines. Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A Front Chem; 2019; 7():602. PubMed ID: 31552220 [TBL] [Abstract][Full Text] [Related]
51. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. El Khissiin A; Journé F; Laïos I; Seo HS; Leclercq G Steroids; 2000 Dec; 65(12):903-13. PubMed ID: 11077089 [TBL] [Abstract][Full Text] [Related]
52. ER subtype selectivity of m-carborane-containing phenols: C-alkyl groups on the m-carborane cage enhance ERα selectivity. Ohta K; Ogawa T; Kato K; Oda A; Endo Y Bioorg Med Chem Lett; 2019 Aug; 29(16):2290-2293. PubMed ID: 31248773 [TBL] [Abstract][Full Text] [Related]
53. Novel estrogen receptor (ER) modulators: carbamate and thiocarbamate derivatives with m-carborane bisphenol structure. Ohta K; Ogawa T; Suzuki T; Ohta S; Endo Y Bioorg Med Chem; 2009 Dec; 17(23):7958-63. PubMed ID: 19857971 [TBL] [Abstract][Full Text] [Related]
54. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173 [TBL] [Abstract][Full Text] [Related]
55. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612 [TBL] [Abstract][Full Text] [Related]
56. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563 [TBL] [Abstract][Full Text] [Related]
57. Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator. Zhang JX; Labaree DC; Mor G; Hochberg RB J Clin Endocrinol Metab; 2004 Jul; 89(7):3527-35. PubMed ID: 15240642 [TBL] [Abstract][Full Text] [Related]
58. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758 [TBL] [Abstract][Full Text] [Related]
59. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells. Liu J; Li J; Sidell N Cancer Chemother Pharmacol; 2007 Feb; 59(2):217-25. PubMed ID: 16738884 [TBL] [Abstract][Full Text] [Related]